Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Joinn Labs to Acquire US-Based Biomere, a Pre-clinical CRO, for $27.3 Million

publication date: May 23, 2019

Joinn Laboratories of Beijing, a CRO, will pay $27.3 million to acquire the pre-clinical CRO business of Boston-area Biomere, formerly known as Biomedical Research Models. Biomere claims particular expertise in animal models. Joinn said the US acquisition will create synergies with its China business and give the company a foothold in Boston, allowing it to access multinational pharmas. Joinn, which will close the transaction after Biomere divests its money-losing vaccine business, plans to form a special purchase vehicle in the US to complete the cash transaction. More details....

Stock Symbol: (SHA: 603127)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.